Literature DB >> 12915636

Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.

Claudio Marcocci1, Luigi Bartalena, Roberto Rocchi, Michele Marinò, Francesca Menconi, Eugenia Morabito, Barbara Mazzi, Salvatore Mazzeo, Maria Sole Sartini, Marco Nardi, Francesco Cartei, Luca Cionini, Aldo Pinchera.   

Abstract

We investigated the long-term side-effects of orbital radiotherapy (OR) in 204 patients with Graves' ophthalmopathy (GO), irradiated from 1972-1996 [44 by cobalt unit (CU) and 160 by linear accelerator (LA), mostly combined with glucocorticoids], with a 5- to 25-yr follow-up (median, 11 yr). Cataract was observed in 21 patients (10%) 3-21 yr after OR, with a higher (not significant) prevalence in CU-treated patients (18% vs. 8% in LA-treated patients). The prevalence of cataract was higher, although not significantly, in CU-treated patients aged less than 60 yr, but not in LA-treated patients, compared with the general population. Mild, asymptomatic retinopathy was observed in 1 of 7 patients (14%) with diabetes and hypertension, in 1 of 31 patients (3%) with hypertension alone, and in 0 of 11 patients with diabetes alone. No tumors were observed in 157 patients submitted to computed tomography scan of orbital and adjacent regions. In conclusion, OR is a safe treatment, not associated with an increased frequency of cataract, provided a high voltage apparatus is used. Hypertension, especially if associated with diabetes, may represent a relative contraindication, as it may cause retinopathy. Although no secondary tumors were detected, due to the long latency of radiation-induced tumors, OR should be restricted to patients older than 35 yr.

Entities:  

Mesh:

Year:  2003        PMID: 12915636     DOI: 10.1210/jc.2003-030260

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 2.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 4.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

5.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  The evaluation and treatment of graves ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Rebecca S Bahn
Journal:  Med Clin North Am       Date:  2012-02-22       Impact factor: 5.456

7.  Secondary malignancy following radiotherapy for thyroid eye disease.

Authors:  Christopher C Gillis; Eun Hae Chang; Khalid Al-Kharazi; Tom Pickles
Journal:  Rep Pract Oncol Radiother       Date:  2016-02-08

8.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

9.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26

10.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.